NCT00353015View on ClinicalTrials.gov

Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract

PHASE2CompletedINTERVENTIONAL

Enrollment

21

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

December 31, 2007

Study Completion Date

July 31, 2009

Conditions

Gastrointestinal CancerCarcinoma, Neuroendocrine

Interventions

DRUG

Cisplatin

Cisplatin 25 mg/m2 IV days 1, 8 of a 21-day cycle

DRUG

Irinotecan

Irinotecan 65 mg/m2 IV days 1, 8 of a 21-day cycle

Trial Locations (1)

77030

U.T. M.D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Pharmacia

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER